An important clinical trial announcement is good news for this healthcare stock. The post Bell Potter is tipping this exciting ASX healthcare stock to rise 80% appeared first on The Motley Fool ...
Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...
This stock is making its shareholders smile on Tuesday. Let's find out why. The post Why is this ASX 200 share charging 7% higher today? appeared first on The Motley Fool Australia.
FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit desired safety and ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...
Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...
The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate ...
New formulation of its widely-used U.S. market-leading PSMA PET imaging agentcombines thediagnostic performance of PYLARIFY® (piflufolastat F 18) ...
The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate cancer imaging agent, aimed at improving scanning access through increased production ...
An investigational approach to diagnosis of prostate cancer uses sound waves to extract "bubbles of information" from cells. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results